DELFI Diagnostics

Categories

Description

A platform leveraging fragmentomics and machine learning for early cancer detection through liquid biopsy.

Summary

DELFI Diagnostics utilizes a novel approach in cancer detection by analyzing cell-free DNA fragments in the bloodstream with advanced machine learning and next-generation sequencing technologies. This method, known as fragmentomics, is designed to support early-stage cancer detection by scanning millions of data points to identify cancer-associated DNA fragments. This scalable approach aims to improve upon existing liquid biopsy methods by detecting previously unrecognized patterns associated with cancer.

Use Cases

• Oncologists use DELFI Diagnostics for early detection of lung cancer in high-risk patients.
• Researchers study the effectiveness of fragmentomics technology in identifying early-stage cancers across diverse patient populations.